Sanjivani Paranteral Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/85ak2n25end0xxx2xgkehnzh.pdf

Key Takeaways


Revenue Growth & Profitability

Ashwani Khemka: "The broader outlook will be only available during the AGM time and we are trying our level best to have it maintain, but we cannot confirm the same speed right now. It would be in the same aspect."

New Facilities: Pune & Prague

Ashwani Khemka: "Yes. As you are asking everything, and we are also very much eager and by god's grace and hope everything, we should have some commercial production in this first quarter."

Geographic & Regulatory Expansion


Product Portfolio & Capacity


Balance Sheet & Working Capital


Guidance & Commitments

CommitmentSpecificsTimeline
Pune facility commercial productionValidation batches complete within 10 days; some commercial production in Q1, full ramp-up from Q2/Q3 onwardQ1 FY26 for initial production; Q2-Q3 FY26 for full ramp-up
Prague JV commercial expansionSignificant expansion in commercial operationsFY26
Product launches15 to 20 new products addedFY26
Debt levelsRemain at March 2025 levelsFY26
Working capitalImproving trend on inventory, payables and receivablesFY26
Francophone Africa revenue contributionGrowth expectedLater end of FY26
Broader FY26 outlookFull guidance providedAt AGM

Key Metrics

MetricQ4 FY25
Revenue₹18.2 cr, +41.3% YoY
EBITDA₹3.1 cr, +37.9% YoY
EBITDA margin16.8%, vs 17.2% in Q4 FY24
Profit after tax₹2.2 cr, +74.4% YoY
Revenue (full year FY25)₹70.1 cr, +28.8% YoY
EBITDA (full year FY25)₹11.6 cr, +32.1% YoY
EBITDA margin (full year FY25)16.5%, vs 16.1% in FY24
Profit after tax (full year FY25)₹8.1 cr, +31.4% YoY
Export-domestic mix72.5% export, 27.5% domestic
Injectable-tablet-nutraceutical dosage mix71.9% injectable, 27% tablet, 1% nutraceutical
New products added in FY2515, total portfolio now at 160 products
New geographies entered in FY255
Capacity utilization, Mumbai plant65%
Capacity utilization, Dehradun plant40%, expected to ramp up to 50–55%
Products filed in Francophone Africa48 during FY25
Capex for Pune HAL JV₹30–35 cr incurred in FY25